Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity

Journal of Medicinal Chemistry

Volumn 44, Issue 12, 2001, Pages 1915-1926

  Schroeder, M C ^a   Hamby, J M ^a   Connolly, C J C ^a   Grohar, P J ^a   Winters, R T ^a   Barvian, M R ^a   Moore, C W ^a   Boushelle, S L ^a   Crean, S M ^a   Kraker, A J ^a   Driscoll, D L ^a   Vincent, P W ^a   Elliott, W L ^a   Lu, G H ^a   Batley, B L ^a   Dahring, T K ^a   Major, T C ^a   Panek, R L ^a   Doherty, A M ^a   Hollis Showalter, H D ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMINOPYRIDO[2,3 D]PYRIMIDIN 7 YLUREA DERIVATIVE; FIBROBLAST GROWTH FACTOR RECEPTOR; GENE PRODUCT; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN C SRC; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; AORTA; ARTICLE; AUTOPHOSPHORYLATION; CELL GROWTH; CONTROLLED STUDY; CYTOTOXICITY; DRUG SYNTHESIS; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; NONHUMAN; RAT; SMOOTH MUSCLE FIBER; STRUCTURE ACTIVITY RELATION; TUMOR CELL; VASCULAR SMOOTH MUSCLE; XENOGRAFT;

3T3 CELLS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; COLONIC NEOPLASMS; ENZYME INHIBITORS; GLIOMA; HUMANS; INDICATORS AND REAGENTS; KINETICS; MICE; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, FIBROBLAST GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION; TUMOR CELLS, CULTURED; UREA;

EID: 0035821591     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0004291     Document Type: Article

References (52)

1. Tyrosine kinase inhibition: An approach to drug development
2. Protein tyrosine kinase inhibitors in cancer treatment
3. Signal transduction pathways as drug targets
4. Receptor tyrosine kinases as targets for inhibition of angiogenesis
5. Angiogenesis in cancer, vascular, rheumatoid and other diseases
6. Current concepts in restenosis following balloon angioplasty
7. Pharmacological inhibition of restenosis: Learning from experience
8. Multiple growth factors are associated with lesions of atherosclerosis: Specificity or redunancy?
9. The epidermal growth factor receptor family of tyrosine kinases and cancer: Can an atypical exemplar be a sound therapeutic target?
10. The protein kinase family: Conserved features and deduced phylogeny of the catalytic domains
11. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
12. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(Phenylamino)-quinazoline- and 4-(Phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions
13. In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase
14. 1-Oxo-3-aryl-1H-indene-2-carboxylic acid derivatives as selective inhibitors of fibroblast growth factor receptor-1 tyrosine kinase
15. Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: Implications for combination treatment with photodynamic therapy
16. Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: Identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors
17. Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor
18. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
19. Design and structureactivity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors
20. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
21. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis
22. Combinatorial target-guided ligand assembly: Identification of potent subtype-selective c-Src inhibitors
23. Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest
24. Biochemical and cellular effects of c-Src kinase selective pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors
25. Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD 089828, a new synthetic protein tyrosine kinase inhibitor
26. Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors
27. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8h)-ones. Structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity
28. 3-(3,5-Dimethoxyphenyl)-1,6-naphthyiidine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF-1 receptor tyrosine kinase
29. c-src
30. The synthesis and SAR of pyrido[2,3-d]-pyrimidine-2,7-diamines in the development of potent water soluble tyrosine kinase inhibitors
31. Conversion of anilines to bis-boc protected N-methylguanidines
32. A mild and efficient method for the preparation of guanidines
33. Preparation of N-bis(aryl)gaunidines from electron deficient amines via masked cabodiimides
34. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain
35. Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors
36. Complete thermodynamic description of h-bonding in the framework of multiplicative approach
37. Model solvent systems for QSAR. Part 3. An LSER analysis of the 'critical quartet.' New light on hydrogen bond strength and directionality
38. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor
39. New colorimetric cytotoxicity assay for anticancer-drug screening
40. c-scr in 60 different cell lines derived from human tumors
41. Epidermal growth factor dependent activation of the Src family kinases
42. c-src with two major signaling pathways in human breast cancer
43. Inhibition of glioma cell growth by a truncated platelet-derived growth factor-β receptor
44. A synthetic inhibitor of the mitogen-activated protein kianse cascade
45. Strategies for the discovery of novel tyrosine kinase inhibitors with anticancer activity
46. Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors
47. Selective inhibition of protein kinase C isozymes by the indolcarbazole goe 6976
48. Quantitative evaluation of anticancer agent activity in experimental animals
49. Sequence and schedule-dependent synergy of trimetrexate in combination with 5-fluorouracil in vitro and in mice
50. Chemotherapy with CI-973 ([SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato (2-)] (2-methyl-1,4-butanediamine-N,N′)platinum, NK121) in combination with standard agents against murine tumors in vivo
51. Anthrapyrazoles, a new class of intercalating agents with high-level, broad spectrum activity against murine tumors